Watch More Highlights
Kathryn Tyler Maples, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses data of key importance for advanced practitioners on patients with multiple myeloma who are heavily pretreated and predominantly triple-class refractory, and who relapse after receiving bispecific antibodies (BiAbs). These patients may still have good outcomes when sequentially treated with other immunologic or T-cell–directed therapeutics such as BiAbs and CAR-T cells (Abstract 821).